Chiesi Ventures and Pfizer Ventures have helped gene therapy developer 4D Molecular Therapeutics complete its series B round.
US-based gene therapy developer 4D Molecular Therapeutics (4DMT) closed a $90m series B round yesterday backed by pharmaceutical firms Chiesi Group and Pfizer.
Hedge fund Viking Global Investors led the round, which included CureDuchenne, Berkeley Catalyst Fund, ArrowMark Partners, Janus Henderson Investors, Biotechnology Value Fund, MiraeAsset Financial Group, Perceptive Advisors and Ridgeback Capital Investments.
The corporates contributed through respective investment vehicles Pfizer Ventures and Chiesi Ventures, the latter managed by Pappas Capital, while non-profit organisation CureDuchenne invested through its CureDuchenne…
